Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Mahesh Kudrimoti; Amarinthia Curtis; Samar Azawi; Francis Worden; Sanford Katz; Douglas Adkins; Marcelo Bonomi; Zack Scott; Jenna Elder; Stephen T. Sonis; Richard Straube; Oreola Donini

doi:10.1016/j.btre.2017.05.002

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini

Radiation Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

Original language	English
Pages (from-to)	24-26
Number of pages	3
Journal	Biotechnology Reports
Volume	15
DOIs	https://doi.org/10.1016/j.btre.2017.05.002
State	Published - Sep 2017

Bibliographical note

Funding Information:
Funding: A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc).

Publisher Copyright:
© 2017 The Authors

Keywords

Cancer supportive care
Dusquetide
Head and neck cancer
Immune
Innate
Oral mucositis

ASJC Scopus subject areas

Biotechnology
Applied Microbiology and Biotechnology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.btre.2017.05.002

Cite this

Kudrimoti, M., Curtis, A., Azawi, S., Worden, F., Katz, S., Adkins, D., Bonomi, M., Scott, Z., Elder, J., Sonis, S. T., Straube, R., & Donini, O. (2017). Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnology Reports, 15, 24-26. https://doi.org/10.1016/j.btre.2017.05.002

@article{435597e59b244b9b97b49a7ec3ba9c4d,

title = "Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients",

abstract = "Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.",

keywords = "Cancer supportive care, Dusquetide, Head and neck cancer, Immune, Innate, Oral mucositis",

author = "Mahesh Kudrimoti and Amarinthia Curtis and Samar Azawi and Francis Worden and Sanford Katz and Douglas Adkins and Marcelo Bonomi and Zack Scott and Jenna Elder and Sonis, {Stephen T.} and Richard Straube and Oreola Donini",

note = "Funding Information: Funding: A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc). Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2017",

month = sep,

doi = "10.1016/j.btre.2017.05.002",

language = "English",

volume = "15",

pages = "24--26",

}

Kudrimoti, M, Curtis, A, Azawi, S, Worden, F, Katz, S, Adkins, D, Bonomi, M, Scott, Z, Elder, J, Sonis, ST, Straube, R & Donini, O 2017, 'Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients', Biotechnology Reports, vol. 15, pp. 24-26. https://doi.org/10.1016/j.btre.2017.05.002

TY - JOUR

T1 - Dusquetide

T2 - Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

AU - Kudrimoti, Mahesh

AU - Curtis, Amarinthia

AU - Azawi, Samar

AU - Worden, Francis

AU - Katz, Sanford

AU - Adkins, Douglas

AU - Bonomi, Marcelo

AU - Scott, Zack

AU - Elder, Jenna

AU - Sonis, Stephen T.

AU - Straube, Richard

AU - Donini, Oreola

N1 - Funding Information: Funding: A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc). Publisher Copyright: © 2017 The Authors

PY - 2017/9

Y1 - 2017/9

N2 - Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

AB - Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

KW - Cancer supportive care

KW - Dusquetide

KW - Head and neck cancer

KW - Immune

KW - Innate

KW - Oral mucositis

UR - http://www.scopus.com/inward/record.url?scp=85020304341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020304341&partnerID=8YFLogxK

U2 - 10.1016/j.btre.2017.05.002

DO - 10.1016/j.btre.2017.05.002

M3 - Article

AN - SCOPUS:85020304341

VL - 15

SP - 24

EP - 26

ER -

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this